Top

International Journal of Colorectal Disease

Published in:

01-09-2006 | Invited Commentary

Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response?

Authors: B. M. Wittig, M. Zeitz

Published in: International Journal of Colorectal Disease | Issue 6/2006

Abstract

Over the past several years, research in the field of cytokine production and function has become indispensable to understand the immunopathology of chronic intestinal inflammation. Thereupon, clinical studies analyzing cytokine production have generated a tremendous amount of data. In patients with inflammatory bowel disease, several studies examined pro-inflammatory cytokines in gut tissue and plasma, but a clear interpretation of the results with respect to disease activity or therapeutic response has been hampered by patient- and sample-related pitfalls.

Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRef

Gotteland M, Lopez M, Munoz C, Saez R, Altshiller H, Llorens P, Brunser O (1999) Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci 44:830–835PubMedCrossRef

Gross V, Andus T, Ceasar I, Roth M, Schoelmerich J (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 102:514–519PubMed

Kusugami K, Ina K, Ando T, Hibi K, Nishio Y, Goto H (2004) Immunomodulatory therapy for inflammatory bowel disease. J Gastroenterol 39:1129–1137PubMedCrossRef

Lieberman BY, Fiocchi C, Youngman KR, Sapatnekar WK, Proffit MR (1988) Interferon-g production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease. Dig Dis Sci 33:1297–1304PubMedCrossRef

Lochs H, Adler G, Beglinger C, Duchmann R, Emmrich J, Ewe K, Gangl A, Gasche C, Hahn E, Hoffmann P, Kaskas B, Malchow H, Pohl C, Raedler A, Renner E, Schölmerich J, Schreiber S, Stange E, Tilg H, Vogelsang H, Weigert N, Zeitz M (1999) Anti-TNF antibody in Crohn’s disease—status of information, comments and recommendations of an international working group. Z Gastroenterol 37:509–512PubMed

Mahida YR, Kurlac L, Gallagher A, Hawkey CJ (1991) High circulating concentrations of interleukin-6 in active Crohn’s disease but not ulcerative colitis. Gut 32:1531–1534PubMedCrossRef

Matsuura T, West GA, Kleins JS, Ferraris L, Fiocchi L (1992) Soluble interleukin-2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology 102:2006–2014PubMed

Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, Masuda J, Handa K, Harada K, Nishida H, Toyonaga A, Sata M (2005) Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 141:130–140PubMedCrossRef

10.

Muratov V, Lundahl J, Ulfgren A, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Lofberg R (2005) Downregulation of interferon-g parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis (in press) http://dx.doi.org/10.1007/s00384-005-0069-2

11.

Niederau C, Backmerhoff F, Schumacher B, Christoph N (1997) Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis. Hepatogastroenterology 44:90–107PubMed

12.

Ogura Y, Imamura Y, Murakami Y, Takesue Y, Yokoyama T, Sueda T, Hiyama E (2005) Intracellular cytokine patterns of peripheral blood T cells as a useful indicator of activeness of Crohn’ disease. Hiroshima J Med Sci 54:1–8PubMed

13.

Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547–557PubMedCrossRef

14.

Rogler G (2004) Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 20:311–317PubMedCrossRef

15.

Sartor RB (1994) Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 106:533–539PubMed

16.

Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T (2003) Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9:307–321PubMedCrossRef

17.

Shinoda T (2002) Photopheresis and leukocytapheresis: cytapheresis treatment against immune-mediated diseases. Ther Apher 6:245–246PubMedCrossRef

Title: Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response?
Authors: B. M. Wittig
M. Zeitz
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 6/2006
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-005-0082-5

2024 ASCO Annual Meeting

Springer Medicine

Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response?

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Emergency subtotal/total colectomy in the management of obstructed left colon carcinoma

Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study

Isolation and cultivation of neuronal precursor cells from the developing human enteric nervous system as a tool for cell therapy in dysganglionosis

“Fast-track” rehabilitation after rectal cancer resection

Increasing anastomosis safety and preventing abdominal adhesion formation by the use of polypeptides in the rat

Is there a role for concomitant pelvic floor repair in patients with sphincter defects in the treatment of fecal incontinence?